Sonothera Claims Duchenne Treatment Potential Without Clinical Data as Animal Results Draw Skepticism
Updated
Updated · STAT · Jul 17
Sonothera Claims Duchenne Treatment Potential Without Clinical Data as Animal Results Draw Skepticism
1 articles · Updated · STAT · Jul 17
Summary
Sonothera has spent the past year touting technology it says could treat Duchenne muscular dystrophy and potentially other genetic diseases, despite having no clinical data yet.
Animal data presented by the California startup appeared so strong that outside experts questioned whether the results were plausible rather than embracing them outright.
Eric Olson of UT-Southwestern said he found the claims hard to believe, while University of Washington gene-therapy expert Jeffrey Chamberlain called them "a bit too good to be true."
The reaction underscores how unusually high the bar is for preclinical Duchenne breakthroughs, especially when a small biotech suggests its platform could extend beyond a single disease.